£3.2M
Epidarex Capital led the seed round to help the Edinburgh spin-out advance its tumour-associated macrophage platform.
Macomics
Macomics develops novel immuno-therapies to overcome resistance in cancer treatments.
£3.2MTotal raised
Macomics is an immuno-oncology company specialising in macrophage biology to create first-in-class cancer therapeutics. The business builds on academic research from the University of Edinburgh to target tumour associated macrophages.
Categories
Founders
JP
Jeffrey Pollard
Director of the MRC Centre for Reproductive Health at the University of Edinburgh
Luca Cassetta
Co-founder
Luca brings immunology and academic research experience from roles at Macomics and The University of Edinburgh. He co-founded Macomics and serves as its VP Immunology.
LinkedIn